

Applicant : Stephen Little et al
Serial No. : 09/889,415
Filed : July 17, 2001
Page : 3

Attorney's Docket No.: 06275-
0001 / SAD/LDG/Z70478/UST

REMARKS


Applicants respectfully request entry of the amendments to the claims as shown herein. More specifically, applicants have amended claims 3-5, 9, 12, and 13 to eliminate multiple dependency while conserving the claimed subject matter. Claims 1-16 are now pending.

Applicants hereby submit that the enclosures fulfill the requirements under 37 C.F.R. §1.821-1.825. The amendments in the specification merely replace the paper copy of the Sequence Listing with an amended Sequence Listing wherein the general information has been updated to include the inventors, attorney docket number, serial number, filing date, and priority information for the instant application. No new matter has been added.

Please apply any other charges or credits to Deposit Account No. 06-1050, referencing attorney docket number 06275-289001.

Respectfully submitted,

Date:

July 26, 2002 

Janis K. Fraser, Ph.D., J.D.
Reg. No. 34,819

Fish & Richardson P.C.
225 Franklin Street
Boston, Massachusetts 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

Applicant : Stephen Little et al
Serial No. : 09/889,415
Filed : July 17, 2001
Page : 4

Attorney's Docket No.: 06275-
9001 / SAD/LDG/Z70478/UST

Version with markings to show changes made

In the claims:

Claims 3-5, 9, 12, and 13 have been amended as follows:

3. (Amended) A support as claimed in claim 1, [or 2] wherein the oligonucleotides are detectably labelled.
4. (Amended) A support as claimed in [any of the preceding claims] claim 1, which comprises at least 50, particularly at least 500 and more particularly at least 5000, distinct oligonucleotides on the support.
5. (Amended) A support as claimed in [any of claims 1 to 4] claim 1, wherein each oligonucleotide is non-complementary with genomic DNA and non complementary with each other.
9. (Amended) A method as claimed in claim 7, [or claim 8] wherein each primer is used in conjunction with a second companion primer to amplify the target region of interest.
12. (Amended) A method as claimed in claim 10, [or claim 11] wherein there are between 5 and 80 distinct targeting oligonucleotides per target gene.
13. (Amended) A method as claimed in claim 10, [11 or 12] wherein step (iii) is carried out as separate reactions between the target cDNAs and separate pools of targeting polynucleotides, the cDNA target binding sequences of the polynucleotides in each pool possessing approximately the same T_m as the others in the pool; the hybridisation reactions from each pool of targeting polynucleotides are then pooled together.